Life Sciences & Healthcare

Spain

CMS Albiñana & Suárez de Lezo provides advice on all aspects affecting the pharmaceutical industry, including domestic and international corporate transactions as well as regulatory, intellectual property and dispute resolution matters relating to product or other forms of liability.

We boast a team of more than 150 lawyers specialising in healthcare and pharmaceutical law with the support of the Lifesciences Asia-Pacific Network (LAN), enabling us to understand the scientific, commercial and legal obligations affecting pharmaceutical companies. We work with the 100 most important pharmaceutical, medical equipment, biotechnology, agriculture and food companies, including 20 pharmaceutical multinationals and nine of the ten biggest medical equipment enterprises.

With active members in key sector associations such as ABPI, ABPI, BIVDA, PAGB, EUCOMED and EFPIA, we contribute to the design of regulatory frameworks affecting the pharmaceutical and healthcare sectors. We advise clients on their daily operational needs, including advertising and promotion, as well as public procurement, price and refund policies, the use of patents, commercial agreements and clinical trials. Moreover, we also provide regulatory advice on complex issues relating to strategic agreements, corporate transactions and legal proceedings for product or other forms of liability.

Read more Read less

Feed

Show only
18/05/2018
EU Product Li­ab­il­ity Dir­ect­ive still an ad­equate tool, ac­cord­ing to...
On 7 May 2018, the European Com­mis­sion pub­lished its fifth re­port on the per­form­ance of the EU Product Li­ab­il­ity Dir­ect­ive (Dir­ect­ive/85/374/EEC) in the mem­ber states. The dir­ect­ive in­tro­duced the concept of strict li­ab­il­ity for pro­du­cers of de­fect­ive products.
17/04/2018
NGOs can ask the Com­mis­sion to re­view its de­cision on ge­net­ic­ally...
The Gen­er­al Court de­cided in its de­cision of 14 March 2018 that non-gov­ern­ment­al or­gan­iz­a­tions (“NGOs”) can ask the Com­mis­sion to re­view its de­cision on au­thor­iz­ing the pla­cing on the mar­ket of ge­net­ic­ally mod­i­fied food and feed.
07/10/2016
Gen­er­al Court of the EU con­firms the Lun­d­beck de­cision of the European...
On 8 Septem­ber 2016, the Gen­er­al Court of the EU ad­op­ted for the first time a judg­ment in a pay-for-delay case in the phar­ma­ceut­ic­al in­dustry. The Court thereby con­firmed the de­cision of the European Com­mis­sion of 19 June 2013 whereby it im­posed a total fine.